๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhanjiang
Clinical trial register · China

Clinical Trials in Zhanjiang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 451 Beijing 25 Shenzhen 23 Zhongshan 17 Nanning 17
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou451 Beijing25 Shenzhen23 Zhongshan17 Nanning17
All 55 locations
Target enrolment
to

Trials with a site in Zhanjiang

12 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study
NCT07589049Head and Neck Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2
42
Foshan, Guangzhou, Qingyuan, Shantou, Shenzhen, Zhanjiang, Ganzhou
2026-05
By invitation
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
NCT07618624Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Sun Yat-sen University
Phase 2
42
Foshan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2026-04-20
Recruiting
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
NCT06768931Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy
Sun Yat-sen University
Phase 2
192
Lanzhou, Dongguan, Guangzhou, Zhanjiang, Zigong
2026-04-01
Recruiting
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
NCT07477626Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation Therapy
Sun Yat-sen University
Phase 3
372
Dongguan, Guangzhou, Zhanjiang, Zhengzhou, Chengdu, Hangzhou, Beijing, Shanghai
2026-03-20
Recruiting
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
NCT07362979Nasopharyngeal Cancinoma (NPC)
DrugsCCRT·GP·TP
Sun Yat-sen University
Phase 2
243
Dongguan, Guangzhou, Shenzhen, Zhanjiang
2026-03-12
Active, closed
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
NCT07201337Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
700
Dongguan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2025-11-17
Active, closed
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT06712888Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 3
466
Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu
2025-02-17
Recruiting
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT06239727Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
593
Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning
2024-03-01
Active, closed
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
NCT05211232Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
450
Zhanjiang, Wuzhou, Guiyang, Changsha
2022-06-10
Recruiting
Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction
NCT06069232Aortic Valve Disease
Sun Yat-sen University
Observational
2,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2021-03-01
Recruiting
Tricuspid RegurgitAtion rIsk modeL Study (TRAIL Study)
NCT06926959Tricuspid Regurgitation
Sun Yat-sen University
Observational
3,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2016-06-15
Recruiting
Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer
NCT02966483Rectal Neoplasms Malignant, Surgery
Sun Yat-sen University
Not applicable
1,114
Beijing, Chongqing, Guangzhou, Zhanjiang, Zunyi, Changsha, Hengyang, Changchun
2016-04
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhanjiang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies with a site in Zhanjiang that also match the filters currently applied.

How many clinical trials are recruiting in Zhanjiang?

7 of the 12 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhanjiang), 12 studies
PhaseStudiesRecruitingShare
Phase 35241.7%
Phase 24233.3%
Observational2216.7%
Not applicable118.3%

Most active sponsors

Lead sponsors with the most studies (Zhanjiang)
Lead sponsorStudiesRecruiting
Sun Yat-sen University127
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.